Pharmaceutical industry

Europe
#Europe #Investment #Pharmaceutical industry

Pharma urges leaders to reverse Europe’s declining competitiveness

An open letter from the chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi has urged European governments to create conditions that attract investment in next-generation medicines.  They argue that Europe is losing ground to global competition, with over $600 billion in pharmaceutical investment announced… Read More

#Business & Investment #Editor's Choice #News

#ABPI #Association of the British Pharmaceutical Industry #Pharmaceutical industry #UK

ABPI paints a “hopeful” picture for the UK pharma industry

The Association of the British Pharmaceutical Industry’s (ABPI’s) 2026 flagship Competitiveness Report finds the UK has begun to reverse years of decline.  However, the Association cautions that sustained delivery of government commitments will now determine whether the recovery holds.  Since September 2025, the global pharmaceutical industry has committed an additional… Read More

#Business & Investment #News

#GlobalData #Investment #Pharmaceutical industry #Politics #Tariffs #UK #United States

Is US foreign policy uncertainty strengthening confidence in the UK?

The recent UK-US policy developments are reshaping global pharmaceutical investment and launch strategies, according to intelligence platform GlobalData.  In December 2025, the UK announced a landmark pharmaceuticals agreement with the US, granting UK-made medicines and medical technologies tariff-free access to the US market for at least three years.   Alongside this,… Read More

#Business & Investment #News #Trending News

UK and US flags
#ABPI #National Institute for Health and Care Excellence (NICE) #Pharmaceutical industry #UK government

UK-US pharmaceuticals deal supports UK life sciences

A trade deal has been agreed between the UK and the US, which the governments says will secure and expand access to drugs, safeguard the medicines supply chain, and “drive crucial investment while supporting UK patients and industries”.   The deal – part of the UK-US Economic Prosperity Deal – sees the… Read More

#Business & Investment #News #Trending News

#Biopharmaceuticals #GlobalData #Market reporting #Pharmaceutical industry

Top biopharma companies report 4% market growth in Q3 2025

The top 20 global biopharmaceutical companies experienced mixed individual market capitalisation performances in Q3 2025, with those experiencing robust pipeline progress reaping success.   This resulted in a 4% quarter-on-quarter (QoQ) increase in their combined market capitalisation from $3.7 trillion on 30 June 2025 to $3.8 trillion on 30 September 2025,… Read More

#Business & Investment #News #Trends & Analysis

#AstraZeneca #Biopharma #Direct-to-Consumer #Pfizer #Pharmaceutical industry #United States

Pharma firms offer discounts of up to 85% to US patients

AstraZeneca has become the latest company to lower the cost of medicines for American patients. The company recently announced an agreement with President Donald Trump’s administration to lower the cost of prescription medicines for American patients “while preserving America’s cutting-edge biopharmaceutical innovation”.  In July, US President Donald Trump sent letters… Read More

#Business & Investment #Editor's Choice #News

#Association of the British Pharmaceutical Industry #Biopharmaceuticals #Pharmaceutical industry #UK government

UK pharma pricing discussions end in stalemate

The Association of the British Pharmaceutical Industry (ABPI) and the UK government have been unable to reach an agreement on changes to a controversial medicines payment scheme.  In April 2025, the ABPI and government agreed to bring forward a planned mid-scheme review of the 2024 Voluntary Scheme… Read More

#News #Trending News

#European Union #GlobalData #Pharmaceutical industry #Politics #United States

Experts weigh the impact of Trump’s proposed tariff on pharma

The pharmaceutical industry is on high alert as US President Donald Trump proposes a 200-250% tariff on drug imports, which could significantly increase prices and reduce profit margins.   While the tariffs are set to be announced soon, a grace period of 12 to 18 months has been indicated before they… Read More

#Business & Investment #News #Trending News

#Big pharma #Europe #Pharmaceutical industry #Switzerland #United States

Trump increases pressure on pharma and imposes new tariffs

US President Donald Trump has sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash US prescription drug prices to match those paid overseas, the White House said on Thursday.  Trump signed an executive order in May demanding drugmakers cut US medicine prices to match… Read More

#Business & Investment #News #Trending News

Downing Street, London, UK
#Life sciences #Pharmaceutical industry #Politics #UK government

Pharma and UK government continue to debate drug prices

A “battle” between the UK government and the pharmaceutical industry over drug prices has forced the government to delay publication of its plan for the life sciences, according to The Financial Times.  The release of the life sciences review, initially scheduled for the start of this week, was delayed in… Read More

#Business & Investment #News #Trending News

Drug prices concept
#Biopharmaceuticals #Drug pricing #Pharmaceutical industry #United States

What international reference pricing could mean for US drug costs

Andrew Mignatti, Co-Founder and CEO of careviso, looks at the possibility of the United States (US) adopting international reference pricing and asks if it is possible to lower drug costs without undermining innovation.  Discussion around international reference pricing (IRP) is intensifying as policymakers search for ways to address persistently high… Read More

#Business & Investment #Exclusive Content #Opinion

#Association of the British Pharmaceutical Industry #Pharmaceutical industry #UK #UK government

UK doubles statutory payment rate on pharma sales

The UK government has doubled the rate that pharmaceutical companies repay on the sales of newer products to the NHS under the statutory scheme for branded medicines to a record 31%.  Following a consultation, the government has decided to raise the statutory scheme payment rate for newer branded medicines from… Read More

#Business & Investment #News

UK financial markets
#Association of the British Pharmaceutical Industry #Investment #Pharmaceutical industry #Research and development #UK #UK government

UK to lose £11bn in pharma R&D investment

The UK could lose out on £11 ($14.8) billion in pharmaceuticals research and development (R&D) investment by 2033, according to WPI Economics.  In the UK, the Voluntary Scheme or VPAG requires companies to pay the Department of Health and Social Care (DHSC) up to a quarter to a third of… Read More

#Business & Investment #News #Trending News

Map of Europe
#EFPIA #European Commission #Investment #Pharmaceutical industry #Survey

European pharma CEOs threaten exodus to the US

CEOs of the research-based pharmaceutical industry have issued a stark warning to the European Commission that unless Europe delivers rapid, radical policy change then pharmaceutical research, development and manufacturing is increasingly likely to be directed towards the US.  A survey of European Federation of Pharmaceutical Industries and Associations (EFPIA) member… Read More

#Business & Investment #News #Trending News

Great British Pounds, Investment
#Association of the British Pharmaceutical Industry #Pharmaceutical industry #UK #UK government

ABPI criticises “excessive” payment rates on branded medicines

The Association of the British Pharmaceutical Industry (ABPI) has warned that “rocketing payment rates are undermining the UK government’s efforts to make life sciences a key pillar of its industrial strategy”.  The government is proposing to raise the Statutory Scheme payment rate for newer branded medicines from… Read More

#News